Answers are grounded in this paper and cite their sources.
Demonstrates cetuximab efficacy strictly in wild-type K-ras advanced colorectal cancer, indicating mutation status dictates treatment response.
Patients with a colorectal tumor bearing mutated K-ras did not benefit from cetuximab, whereas patients with a tumor bearing wild-type K-ras did benefit from cetuximab. The mutation status of the K-ras gene had no influence on survival among patients treated with best supportive care alone. (ClinicalTrials.gov number, NCT00079066.)
No takes yet. Share an insight, caveat, or question.
Karapetis et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: